Table 2.
Initial and maintenance therapeutic regimens.
| Treatment Regimens | |
|---|---|
| Initial, n (%) | |
| Bevacizumab-mFOLFOX6 | 22 (48%) |
| Bevacizumab-FOLFIRI | 13 (28%) |
| Bevacizumab-CapOX | 2 (4%) |
| Bevacizumab-CapIRI | 9 (20%) |
| Maintenance, n (%) | |
| Bevacizumab-mFOLFOX6 | 4 (9%) |
| Bevacizumab-FOLFIRI | 5 (10%) |
| Bevacizumab-CapIRI | 9 (20%) |
| Bevacizumab-De Gramont | 11 (24%) |
| Bevacizumab-Capecitabine | 3 (7%) |
| Bevacizumab monotherapy | 14 (30%) |
Bevacizumab-mFOLFOX6 (bevacizumab 5 mg/kg, oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, fluorouracil 400 mg/m2 bolus, fluorouracil 2400 mg/m2 over 46 h every 2 weeks), Bevacizumab-FOLFIRI (bevacizumab 5 mg/kg, irinotecan 180 mg/m2, folinic acid 400 mg/m2, fluorouracil 400 mg/m2 bolus, fluorouracil 2400 mg/m2 over 46 h every 2 weeks), Bevacizumab-CapOX (bevacizumab 7.5 mg/kg on Day 1, oxaliplatin 130 mg/m2 on d1, capecitabine 1000 mg/m2/12 h Days 1–14 every 3 weeks), Bevacizumab-CapIRI (bevacizumab 7.5 mg/kg on Day 1, irenotecan 250 mg/m2 on d1, capecitabine 1000 mg/m2/12 h Days 1–14 every 3 weeks), Bevacizumab-De Gramont (bevacizumab 5 mg/kg, folinic acid 200 mg/m2 on Days 1,2, fluorouracil 400 mg/m2 bolus on Days 1,2, fluorouracil 2400 mg/m2 over 22 h on Days 1,2 every 2 weeks), Bevacizumab-Capecitabine (bevacizumab 7.5 mg/kg on Day 1, capecitabine 1000 mg/m2/12 h Days 1–14 every 3 weeks), Bevacizumab monotherapy (5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks).